Arca
Skip to content
Tools
Tools

HSD3B2: 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2

3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on HSD3B2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Trilostane

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        TrilostaneApprovedSanofiSmall moleculeInhibitor3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type II inhibitor0

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency
        0.81
        Adrenal gland disorder
        0.37
        Hereditary disease
        0.19
        Cone-rod dystrophy
        0.08
        Leber congenital amaurosis
        0.08
        Achromatopsia
        0.08
        Duane retraction syndrome
        0.08
        Congenital stationary night blindness
        0.08

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3670, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P26439, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.